Qiagen develops and markets biological sample preparation and analysis products for academic, biopharmaceutical and molecular diagnostics companies. These products are considered standards by these customers.
Qiagen has experienced impressive double-digit revenue growth over the last few years, in part driven by increased exposure to MDx.
Over the last few years, Qiagen has started a transition from life science research tools to molecular diagnostic(MDx),triggered by the strategic acquisition of Digene. This transaction reflects the increasing interest research tools companies have for the attractive MDx market, a ~$4B market that is experiencing double digit growth.
This report reviews Qiagen’s financials over the last five years, and presents an analysis of the company’s revenue breakdown by product class (reagents, instrument, services), customer type (academia, Biopharma, applied markets,MDx) and geography (U.S., Europe, Asia, ROW). We present some of the key MDx transactions Qiagen executed and discuss their impact.
Qiagen’s primary addressable markets — MDx and sample preparation — are analyzed in depth. Market size, growth and trends are determined and reviewed. The major competitors are discussed, with an emphasis on sample preparation competitors (e.g., Macherey-Nagel, Life Technologies) and MDx players (e.g.Roche, Abbott). Key HPV test platforms from Hologic, Roche and Gen-probe are benchmarked and their current and future market share estimated.
We describe the highly regulated MDx environment Qiagen plays in. Based on this information, we performed a SWOT analysis that may be used to inform the company’s strategy. |
